FuturedMe was introduced in Nikkei Biotechnology & Business Online as “ creating new medical drugs with innovative target protein degradation technology and having raised around 700 million yen as Series A.”
2019.06.07
FuturedMe was introduced in Nikkei Biotechnology & Business Online